Bayesian Capital Management’s Altimmune ALT Stock Holding History

Bayesian Capital Management’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-14,300	Closed	-$55.3K	–	521
2025 Q2	$55.3K	Buy	+14,300	New	+$77.4K	0.01%	504
2025 Q1	–	Sell	-14,700	Closed	-$106K	–	589
2024 Q4	$106K	Buy	+14,700	New	+$112K	0.01%	610
2023 Q3	–	Sell	-30,175	Closed	-$107K	–	682
2023 Q2	$107K	Buy	30,175 +1,500	+5%	+$6.74K	0.01%	687
2023 Q1	$121K	Buy	+28,675	New	+$341K	0.02%	668
2022 Q4	–	Sell	-25,409	Closed	-$324K	–	759
2022 Q3	$324K	Buy	+25,409	New	+$375K	0.07%	394
2022 Q2	–	Sell	-16,800	Closed	-$102K	–	765
2022 Q1	$102K	Buy	+16,800	New	+$124K	0.02%	696

Other funds holding ALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bayesian Capital Management's ALT Position: Q3 2025 in Review

Bayesian Capital Management sold out of Altimmune (ALT) in Q3 2025, closing a stake of 14,300 shares — an estimated $55.3K sold.

Bayesian Capital Management first reported a position in ALT in Q1 2022 and held it in 6 quarters. The position peaked at $324K in Q3 2022. 158 funds tracked by Wall St. Rank hold ALT as of Q3 2025.

Bayesian Capital Management reported no remaining Altimmune position as of Q3 2025 after selling out during the quarter.
Bayesian Capital Management sold 14,300 Altimmune shares in Q3 2025, an estimated $55.3K.
Bayesian Capital Management first reported a position in Altimmune in Q1 2022 and held it in 6 quarters.
Bayesian Capital Management's Altimmune position peaked at $324K in Q3 2022.
158 funds tracked by Wall St. Rank held Altimmune as of Q3 2025.

Based on Bayesian Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.